Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Лечебное дело
2018 / N 2

Современные представления о выборе фиксированных комбинаций антигипертензивных препаратов: фокус на эффективность и прогноз
О.Д. Остроумова, А.И. Кочетков, Е.Е. Павлеева, Т.Ф. Гусева

Список литературы

1. Чазова И.Е., Ощепкова Е.В., Жернакова Ю.В., Карпов Ю.А., Архипов М.В., Барбараш О.Л., Галявич А.С., Гринштейн Ю.И., Ерегин С.Я., Карпов Р.С., Кисляк О.А., Кобалава Ж.Д., Конради А.О., Кухарчук В.В., Литвин А.Ю., Мартынов А.И., Медведева И.В., Милягин В.А., Небиеридзе Д.В., Невзорова В.А., Огарков М.Ю., Остроумова О.Д., Перепеч Н.Б., Петричко Т.А., Подзолков В.И., Рогоза А.Н., Скибицкий В.В., Терещенко С.Н., Ткачева О.Н., Трубачева И.А., Туев А.В., Тюрина Т.В., Фомин В.В., Чихладзе Н.М., Чукаева И.И., Шалаев С.В., Шестакова М.В., Шлык С.В., Шапошник И.И., Якушин С.С. Диагностика и лечение артериальной гипертонии. Клинические рекомендации. М.; 2013. 64 с. Доступно по http://www.gipertonik.ru/files/recommendation/Recommendations_hypertension.docx Ссылка активна на 20.06.2018.
2. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F; Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension 2013 Jul;31(7):1281-357.
3. Шальнова C., Кукушкин C., Маношкина Е., Тимофеева Т. Артериальная гипертензия и приверженность терапии. Врач 2009;12:39-42.
4. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005 Sep;366(9489):895-906.
5. Горбунов В.М. Современные представления о вариабельности артериального давления. Рациональная фармакотерапия в кардиологии 2012;8(6):810-8.
6. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlöf B, Sever PS, Poulter NR. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure and episodic hypertension. Lancet 2010 Mar;375(9718):895-905.
7. Höcht C. Blood pressure variability: prognostic value and therapeutic implications. ISRN Hypertension 2013;2013:398485.
8. Parati G, Pomidossi G, Albini F, Malaspina D, Mancia G. Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension. Journal of Hypertension 1987 Feb;5(1):93-8.
9. Mancia G, Parati G, Hennig M, Flatau B, Omboni S, Glavina F, Costa B, Scherz R, Bond G, Zanchetti A; ELSA Investigators. Relation between blood pressure variability and carotid artery damage in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis (ELSA). Journal of Hypertension 2001 Nov;19(11):1981-9.
10. Sega R, Corrao G, Bombelli M, Beltrame L, Facchetti R, Grassi G, Ferrario M, Mancia G. Blood pressure variability and organ damage in a general population: results from the PAMELA study (Pressioni Arteriose Monitorate E Loro Associazioni). Hypertension 2002 Feb;39(2 Pt 2):710-4.
11. McMullan CJ, Bakris GL, Phillips RA, Forman JP. Association of BP variability with mortality among African Americans with CKD. Clinical Journal of the American Society of Nephrology 2013 May;8(5):731-8.
12. Kawai T, Ohishi M, Kamide K, Nakama C, Onishi M, Ito N, Takami Y, Takeya Y, Rakugi H. Differences between daytime and nighttime blood pressure variability regarding systemic atherosclerotic change and renal function. Hypertension Research 2013 Mar;36(3):232-9.
13. Schillaci G, Bilo G, Pucci G, Laurent S, Macquin-Mavier I, Boutouyrie P, Battista F, Settimi L, Desamericq G, Dolbeau G, Faini A, Salvi P, Mannarino E, Parati G. Relationship between short-term blood pressure variability and large-artery stiffness in human hypertension: findings from 2 large databases. Hypertension 2012 Aug;60(2):369-77.
14. Schutte AE, Schutte R, Huisman HW, van Rooyen JM, Fourie CM, Malan NT, Malan L. Blood pressure variability is significantly associated with ECG left ventricular mass in normotensive Africans: The SABPA Study. Hypertension Research 2011 Oct;34(10):1127-34.
15. Sakakura K, Ishikawa J, Okuno M, Shimada K, Kario K. Exaggerated ambulatory blood pressure variability is associated with cognitive dysfunction in the very elderly and quality of life in the younger elderly. American Journal of Hypertension 2007 Jul;20(7):720-7.
16. Parati G, Ulian L, Santucciu C, Omboni S, Mancia G. Blood pressure variability, cardiovascular risk and antihypertensive treatment. Journal of Hypertension. Supplement 1995 Dec;13(4):S27-34.
17. Frattola A, Parati G, Cuspidi C, Albini F, Mancia G. Prognostic value of 24-hour blood pressure variability. Journal of Hypertension 1993 Oct;11(10):1133-7.
18. Verdecchia P, Angeli F, Gattobigio R, Rapicetta C, Reboldi G. Impact of blood pressure variability on cardiac and cerebrovascular complications in hypertension. American Journal of Hypertension 2007 Feb;20(2):154-61.
19. Rothwell PM, Howard SC, Dolan E, O’Brien E, Dobson JE, Dahlöf B, Poulter NR, Sever PS; ASCOT-BPLA and MRC Trial Investigators. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. The Lancet. Neurology 2010 May;9(5):469-80.
20. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003 Sep;362(9386):782-8.
21. Остроумова О.Д., Дудаев В.А., Фомина В.М. Артериальная гипертония и ишемическая болезнь сердца: как правильно выбрать лекарственные препараты. Лечебное дело 2014;4:41-9.
22. Scientific Committee of the PERTINENT Sub-Study, EUROPA-PERTINENT Investigators. PERTINENT – perindopril-thrombosis, inflammation, endothelial dysfunction and neurohormonal activation trial: a sub-study of the EUROPA study. Cardiovascular Drugs and Therapy 2003 Jan;17(1):83-91.
23. Bots M., Remme W, Lüscher TF, Simoons ML, Fox KM, Bertrand M, Ferrari R, Grobbee DE; EUROPA-PERFECT Investigators. ACE inhibition and endothelial function: the PERFECT study, sub-study of the EUROPA trial: main findings. Journal of Hypertension 2005;23(Suppl 2):S21. Abstract 3B.4.
24. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, Berman L, Shi H, Buebendorf E, Topol EJ; CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT study: a randomized controlled trial. JAMA 2004 Nov;292(18):2217-25.
25. Соколов И., Гафанович Е. Терапия в раннем постинфарктном периоде пациентки с артериальной гипертензией и хронической сердечной недостаточностью. Врач 2013;9:45-50.
26. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, Riley W. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000 Sep;102(13):1503-10.
27. Final report. Non-intervention monitoring of efficacy and safety of fixed-dose combination of perindopril and amlodipine in the treatment of arterial hypertension. Data on file, Krka, d. d., Novo mesto, Slovenia, 2014.
28. Gradman AH. Rationale for triple-combination therapy for management of high blood pressure. The Journal of Clinical Hypertension (Greenwich) 2010 Nov;12(11):869-78.
29. Gradman AH, Basile JN, Carter BL, Bakris GL; American Society of Hypertension Writing Group. Combination therapy in hypertension. Journal of the American Society of Hypertension 2010 Jan-Feb;4(1):42-50.
30. Конради А.О., Полуничева Е.В. Недостаточная приверженность к лечению артериальной гипертензии: причины и пути коррекции. Артериальная гипертензия 2004;10(3):137-43.
31. Остроумова О.Д., Смолярчук Е.А., Бондарец О.В., Павлеева Е.Е. Клинические преимущества телмисартана: особенности фармакокинетики, фармакодинамики и возможности контроля артериального давления в течение суток. Рациональная фармакотерапия в кардиологии 2017;13(4):550-7.
32. Calleja Rivero JL, Zerpa F, Rivera L. Fixed-dose versus separate drug combinations for antihypertensive treatment: literature review. Medwave 2016 Sep;16(8):e6549.
33. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010 Feb;55(2):399-407.
34. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. The American Journal of Medicine 2007 Aug;120(8):713-9.
35. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. The New England Journal of Medicine 2008 Dec;359(23):2417-28.
36. Patel A; ADVANCE Collaborative Group, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007 Sep;370(9590):829-40.
37. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001 Sep;358(9287):1033-41.
38. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. The New England Journal of Medicine 2008 May;358(18):1887-98.
39. Gosse P, Sheridan DJ, Dubourg O. Diuretics versus angiotensin-converting enzyme inhibitors in the regression of left ventricular hypertrophy in hypertensive patients: the LIVE study. Journal of Hypertension 1999;17(Suppl 3):S73.
40. Marre M, Garcia Puig J, Kokot F, Fernandez M, Jermendy G, Opie L, Moyseev V, Scheen A, Ionescu-Tirgoviste C, Saldanha MH, Halabe A, Williams B, Mion D Jr, Ruiz M, Hermansen K, Tuomilehto J, Finizola B, Pozza G, Chastang C, Ollivier JP, Amouyel P, Asmar R. Effect of indapamide SR on microalbuminuria – the NESTOR study (Natrilix SR versus Enalapril Study in Type 2 diabetic hypertensives with micrOalbuminuRia) – rationale and protocol for the main trial. Journal of Hypertension. Supplement 2003 Mar;21(1):S19-24.
41. Mironneau J. Indapamide-induced inhibition of calcium movement in smooth muscles. The American Journal of Medicine 1988;84:10-4.
42. Sassard J, Bataillard A, McIntyre H. An overview of the pharmacology and clinical efficacy of indapamide sustained release. Fundamental & Clinical Pharmacology 2005 Dec;19(6):637-45.
43. Tóth K; PIANIST Investigators. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients). American Journal of Cardiovascular Drugs 2014 Apr;14(2):137-45.
44. Páll D, Szántó I, Szabó Z. Triple combination therapy in hypertension: the antihypertensive efficacy of treatment with perindopril, amlodipine, and indapamide SR. Clinical Drug Investigation 2014 Oct;34(10):701-8.

References

1. Chazova IE, Oshchepkova EV, Zhernakova YuV, Karpov YuA, Arkhipov MV, Barbarash OL, Galyavich AS, Greenstein YuI, Eregin SYa, Karpov RS, Kislyak OA, Kobalava ZhD, Konradi AO, Kukharchuk VV, Litvin AYu, Martynov AI, Medvedeva IV, Milyagin VA, Nebieridze DV, Nevzorova VA, Ogarkov MYu, Ostroumova OD, Perepech NB, Petrichko TA, Podzolkov VI, Rogoza AN, Skibitskiy VV, Tereshchenko SN, Tkacheva ON, Trubacheva IA, Tuev AV, Tyurina TV, Fomin VV, Chikhladze NM, Chukaeva II, Shalaev SV, Shestakova MV, Shlyk SV, Shaposhnik II, Yakushin SS. Diagnostics and treatment of arterial hypertension. Clinical guidelines. Moscow, 2013. 64 p. Available from: http://www.gipertonik.ru/files/recommendation/Recommendations_hypertension.docx Accessed 2018 Jun 20 (In Russian).
2. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F; Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension 2013 Jul;31(7):1281-357.
3. Shalnova S, Kukushkin S, Manoshkina E, Timofeeva T. Arterial hypertension and adherence to therapy. Vrach (The Doctor) 2009;12:39-42 (In Russian).
4. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005 Sep;366(9489):895-906.
5. Gorbunov VM. Modern views on the variability of blood pressure. Rational Pharmacotherapy in Cardiology 2012;8(6):810-8 (In Russian).
6. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlöf B, Sever PS, Poulter NR. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure and episodic hypertension. Lancet 2010 Mar;375(9718):895-905.
7. Höcht C. Blood pressure variability: prognostic value and therapeutic implications. ISRN Hypertension 2013;2013:398485.
8. Parati G, Pomidossi G, Albini F, Malaspina D, Mancia G. Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension. Journal of Hypertension 1987 Feb;5(1):93-8.
9. Mancia G, Parati G, Hennig M, Flatau B, Omboni S, Glavina F, Costa B, Scherz R, Bond G, Zanchetti A; ELSA Investigators. Relation between blood pressure variability and carotid artery damage in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis (ELSA). Journal of Hypertension 2001 Nov;19(11):1981-9.
10. Sega R, Corrao G, Bombelli M, Beltrame L, Facchetti R, Grassi G, Ferrario M, Mancia G. Blood pressure variability and organ damage in a general population: results from the PAMELA study (Pressioni Arteriose Monitorate E Loro Associazioni). Hypertension 2002 Feb;39(2 Pt 2):710-4.
11. McMullan CJ, Bakris GL, Phillips RA, Forman JP. Association of BP variability with mortality among African Americans with CKD. Clinical Journal of the American Society of Nephrology 2013 May;8(5):731-8.
12. Kawai T, Ohishi M, Kamide K, Nakama C, Onishi M, Ito N, Takami Y, Takeya Y, Rakugi H. Differences between daytime and nighttime blood pressure variability regarding systemic atherosclerotic change and renal function. Hypertension Research 2013 Mar;36(3):232-9.
13. Schillaci G, Bilo G, Pucci G, Laurent S, Macquin-Mavier I, Boutouyrie P, Battista F, Settimi L, Desamericq G, Dolbeau G, Faini A, Salvi P, Mannarino E, Parati G. Relationship between short-term blood pressure variability and large-artery stiffness in human hypertension: findings from 2 large databases. Hypertension 2012 Aug;60(2):369-77.
14. Schutte AE, Schutte R, Huisman HW, van Rooyen JM, Fourie CM, Malan NT, Malan L. Blood pressure variability is significantly associated with ECG left ventricular mass in normotensive Africans: The SABPA Study. Hypertension Research 2011 Oct;34(10):1127-34.
15. Sakakura K, Ishikawa J, Okuno M, Shimada K, Kario K. Exaggerated ambulatory blood pressure variability is associated with cognitive dysfunction in the very elderly and quality of life in the younger elderly. American Journal of Hypertension 2007 Jul;20(7):720-7.
16. Parati G, Ulian L, Santucciu C, Omboni S, Mancia G. Blood pressure variability, cardiovascular risk and antihypertensive treatment. Journal of Hypertension. Supplement 1995 Dec;13(4):S27-34.
17. Frattola A, Parati G, Cuspidi C, Albini F, Mancia G. Prognostic value of 24-hour blood pressure variability. Journal of Hypertension 1993 Oct;11(10):1133-7.
18. Verdecchia P, Angeli F, Gattobigio R, Rapicetta C, Reboldi G. Impact of blood pressure variability on cardiac and cerebrovascular complications in hypertension. American Journal of Hypertension 2007 Feb;20(2):154-61.
19. Rothwell PM, Howard SC, Dolan E, O’Brien E, Dobson JE, Dahlöf B, Poulter NR, Sever PS; ASCOT-BPLA and MRC Trial Investigators. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. The Lancet. Neurology 2010 May;9(5):469-80.
20. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003 Sep;362(9386):782-8.
21. Ostroumova OD, Dudaev VA, Fomina VM. Arterial hypertension and ischemic heart disease: making the right choice of treatment. Lechebnoe Delo 2014;4:41-9 (In Russian).
22. Scientific Committee of the PERTINENT Sub-Study, EUROPA-PERTINENT Investigators. PERTINENT – perindopril-thrombosis, inflammation, endothelial dysfunction and neurohormonal activation trial: a sub-study of the EUROPA study. Cardiovascular Drugs and Therapy 2003 Jan;17(1):83-91.
23. Bots M., Remme W, Lüscher TF, Simoons ML, Fox KM, Bertrand M, Ferrari R, Grobbee DE; EUROPA-PERFECT Investigators. ACE inhibition and endothelial function: the PERFECT study, sub-study of the EUROPA trial: main findings. Journal of Hypertension 2005;23(Suppl 2):S21. Abstract 3B.4.
24. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, Berman L, Shi H, Buebendorf E, Topol EJ; CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT study: a randomized controlled trial. JAMA 2004 Nov;292(18):2217-25.
25. Sokolov I, Gafanovich E. Early post-infarction therapy in a female patient with hypertension and chronic heart failure. Vrach (The Doctor) 2013;9:45-50 (In Russian).
26. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, Riley W. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000 Sep;102(13):1503-10.
27. Final report. Non-intervention monitoring of efficacy and safety of fixed-dose combination of perindopril and amlodipine in the treatment of arterial hypertension. Data on file, Krka, d. d., Novo mesto, Slovenia, 2014.
28. Gradman AH. Rationale for triple-combination therapy for management of high blood pressure. The Journal of Clinical Hypertension (Greenwich) 2010 Nov;12(11):869-78.
29. Gradman AH, Basile JN, Carter BL, Bakris GL; American Society of Hypertension Writing Group. Combination therapy in hypertension. Journal of the American Society of Hypertension 2010 Jan-Feb;4(1):42-50.
30. Konradi AO, Polunicheva EV. Inadequate adherence to treatment of arterial hypertension: causes and ways of correction. Arterial Hypertension 2004;10(3):137-43 (In Russian).
31. Ostroumova OD, Smolyarchuk EA, Bondarets OV, Pavleeva EE. Clinical advantages of telmisartan: features of pharmacokinetics, pharmacodynamics and effects on the daily blood pressure profile. Rational Pharmacotherapy in Cardiology 2017;13(4):550-7 (In Russian).
32. Calleja Rivero JL, Zerpa F, Rivera L. Fixed-dose versus separate drug combinations for antihypertensive treatment: literature review. Medwave 2016 Sep;16(8):e6549.
33. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010 Feb;55(2):399-407.
34. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. The American Journal of Medicine 2007 Aug;120(8):713-9.
35. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. The New England Journal of Medicine 2008 Dec;359(23):2417-28.
36. Patel A; ADVANCE Collaborative Group; MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007 Sep;370(9590):829-40.
37. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001 Sep;358(9287):1033-41.
38. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. The New England Journal of Medicine 2008 May;358(18):1887-98.
39. Gosse P, Sheridan DJ, Dubourg O. Diuretics versus angiotensin-converting enzyme inhibitors in the regression of left ventricular hypertrophy in hypertensive patients: the LIVE study. Journal of Hypertension 1999;17(Suppl 3):S73.
40. Marre M, Garcia Puig J, Kokot F, Fernandez M, Jermendy G, Opie L, Moyseev V, Scheen A, Ionescu-Tirgoviste C, Saldanha MH, Halabe A, Williams B, Mion D Jr, Ruiz M, Hermansen K, Tuomilehto J, Finizola B, Pozza G, Chastang C, Ollivier JP, Amouyel P, Asmar R. Effect of indapamide SR on microalbuminuria – the NESTOR study (Natrilix SR versus Enalapril Study in Type 2 diabetic hypertensives with micrOalbuminuRia) – rationale and protocol for the main trial. Journal of Hypertension. Supplement 2003 Mar;21(1):S19-24.
41. Mironneau J. Indapamide-induced inhibition of calcium movement in smooth muscles. The American Journal of Medicine 1988;84:10-4.
42. Sassard J, Bataillard A, McIntyre H. An overview of the pharmacology and clinical efficacy of indapamide sustained release. Fundamental & Clinical Pharmacology 2005 Dec;19(6):637-45.
43. Tóth K; PIANIST Investigators. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients). American Journal of Cardiovascular Drugs 2014 Apr;14(2):137-45.
44. Páll D, Szántó I, Szabó Z. Triple combination therapy in hypertension: the antihypertensive efficacy of treatment with perindopril, amlodipine, and indapamide SR. Clinical Drug Investigation 2014 Oct;34(10):701-8.
  

[ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]